Transforming Multiomics Spatial Tissue Biology with the Power of MALDI Mass Spectrometry for Imaging Targeted Proteins, Lipids, Glycans and Metabolites
WATERTOWN, Mass., April 09, 2022–(BUSINESS WIRE)–AmberGen Inc., a Boston-area life sciences technology company, today announced the closing of a strategic investment from Bruker Corporation, a world leader in scientific instrumentation and life science solutions. AmberGen’s innovative and proprietary Miralys® Space Biology Imaging Reagents for MALDI-based Immunohistochemistry (MALDI-IHC) are currently in beta.
“Transforming Multiomics Spatial Tissue Imaging with MALDI Mass Spectrometry.“
Combined with Bruker’s ultra-high-speed (10 kHz) and high spatial resolution (5 µm) MALDI imaging mass spectrometers, such as Bruker’s rapifleX® and timsTOF fleX™ systems, the new Miralys workflows produce tissue images of targeted protein biomarkers in both fresh frozen and formalin-fixed paraffin-embedded (FFPE) tissue samples. AmberGen’s unique photocleavable peptide-encoded mass tag (PCMT) technology enables high-plex MALDI-MS imaging to detect high-plex panels (up to approximately 100 plexes) of targeted proteins on sections of tissues with a variable and wide field of view (up to 25 mm by 75 mm), suitable for tissue and pathological research. MALDI-IHC workflows are uniquely multiomics in that they are able to image small molecule drugs, their metabolites, glycans, and lipids, in addition to protein biomarkers targeted by IHC. All of this is done on the same tissue slide with a wider field of view than many other mass cytometry imaging approaches.
Miralys reagents make MALDI-IHC both multiomics and multimodal since its optional dual-labeled reagents enable spatial co-registration of multiple imaging modalities, including those based on mass spectrometry, immunofluorescence imaging up to 5 probes and bright field microscopy. Miralys MALDI-IHC workflows are not applicable to subcellular or single small cell imaging, nor to DNA, methylation or mRNA imaging, and therefore complement d other spatial transcriptomic microscopy methods.
Dr Michael Easterling, The Imaging Director of Bruker’s Life Sciences Mass Spectrometry Division, said, “The MALDI-MS tissue imaging community has long expressed a desire to spatially map targeted proteins, as well as glycans, lipids, drugs and their metabolites, where MALDI has found utility using a label-free approach.The innovative photocleavable peptide code mass tag technology developed by AmberGen for tagging proteins of interest is a perfect combination for large field of view, multiomics and multimodal tissue biology spatial applications. This additional information will be fundamentally important for oncology and immuno-oncology research, and pathology research.”
Dr Kenneth RothschildFounder and Executive Chairman of AmberGen, Inc., said, “The Miralys® MALDI-IHC platform provides the life sciences market with very high multiplexed, multiomics and multimodal imaging capabilities to understand complex mechanisms of disease. and response to pharmaceutical treatment. This strategic investment from Bruker will accelerate the introduction of the Miralys space biology approach to a wide variety of researchers and catalyze progress in critical areas such as tissue pathology research and drug development. We are confident that ‘this is the start of a new generation of tissue imaging with built-in multiomics capabilities.’
Dr. Mark Lim, The Executive Vice President and CSO of AmberGen, noted that “the key to the superior performance of our Miralys reagents stems from our innovative mass labels which provide fast and efficient photocleavage and robust probe labeling as well as workflows optimized for high-plex multiomics imaging.”
About AmberGen Inc. – http://www.AmberGen.com
AmberGen, Inc. is a private, Boston-area company founded in 1995 to commercialize pioneering photonics technology developed at Boston University’s Molecular Biophysics Laboratory and Photonics Center. AmberGen’s development of proprietary Peptide-Coded Photocleavable Linkers (PC-Linker™) has led to the early introduction of novel photocleavable reagents, such as PC-Biotin and PC-Phosphoramidites which underpin several commercial proteomics and genomics technologies majors. The company’s mission is to innovate in the field of therapeutics and diagnostics by solving key problems that limit the progress of medicine. AmberGen’s approach combines patented techniques in proteomics and light-based biomolecule monitoring.
See the source version on businesswire.com: https://www.businesswire.com/news/home/20220408005612/en/
For AmberGen, John Gillespie, CEO, AmberGen Inc., Email [email protected]